Valuation: CorMedix Inc.

Market Cap 59Cr 53Cr 49Cr 44Cr 83Cr 5.59TCr 84Cr 582.96Cr 229.11Cr 2.93TCr 221.31Cr 216.72Cr 9.34TCr P/E 2026 *
15.3x
P/E 2027 * 134x
Enterprise Value 48Cr 43Cr 40Cr 36Cr 68Cr 4.55TCr 69Cr 474.85Cr 186.62Cr 2.38TCr 180.27Cr 176.53Cr 7.61TCr EV / Sales 2026 *
1.43x
EV / Sales 2027 * 1.53x
Free-Float
92.39%
Yield 2026 *
-
Yield 2027 * -
1 day+2.57%
1 week+1.47%
Current month-1.69%
1 month-1.94%
3 months-10.10%
6 months+2.44%
Current year-34.91%
1 week 7.24
Extreme 7.235
7.7
1 month 7.06
Extreme 7.055
8.18
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
13.02
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 10/05/2022
Director of Finance/CFO 54 29/08/2025
Compliance Officer 66 12/12/2023
Director TitleAgeSince
Director/Board Member 67 06/08/2015
Chairman 81 03/08/2017
Director/Board Member 70 16/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Exercice

Director

97,818 0.1255%
29/08/26 Tax

Chief Financial Officer

-8,424 0.0108%
29/08/26 Tax

Compliance Officer

-8,424 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
+2.57%+1.47%-25.64%+134.37% 58Cr
+3.49%+8.54%+59.89%+117.27% 1,10600Cr
+2.19%-1.66%+34.23%+70.27% 61TCr
+2.26%+2.83%+25.92%+98.65% 50TCr
+2.58%+8.31%+37.43%+63.51% 37TCr
+3.25%+1.96%+74.90%+47.67% 35TCr
+1.85%+5.45%+21.38%+49.26% 29TCr
+1.76%+4.92%+0.48%+20.31% 26TCr
+3.29%+5.12%+46.90%+56.43% 23TCr
+2.25%+4.04%+27.44%+99.53% 19TCr
Average +1.02%+1.81%+30.29%+75.73% 39.01TCr
Weighted average by Cap. +0.46%+2.30%+41.68%+80.34%

Financials

2026 *2027 *
Net sales 34Cr 30Cr 28Cr 25Cr 47Cr 3.19TCr 48Cr 333.02Cr 130.88Cr 1.67TCr 126.43Cr 123.8Cr 5.34TCr 29Cr 26Cr 24Cr 22Cr 41Cr 2.74TCr 41Cr 285.8Cr 112.32Cr 1.43TCr 108.5Cr 106.24Cr 4.58TCr
Net income 4.57Cr 4.07Cr 3.77Cr 3.42Cr 6.42Cr 432.8Cr 6.51Cr 45Cr 18Cr 226.46Cr 17Cr 17Cr 722.86Cr 53.29L 47.47L 44.01L 39.85L 74.95L 51Cr 76.01L 5.27Cr 2.07Cr 26Cr 2Cr 1.96Cr 84Cr
Net Debt -11Cr -9.75Cr -9.04Cr -8.18Cr -15Cr -1.04TCr -16Cr -108.11Cr -42Cr -542.6Cr -41Cr -40Cr -1.73TCr -15Cr -13Cr -12Cr -11Cr -21Cr -1.4TCr -21Cr -145.56Cr -57Cr -730.55Cr -55Cr -54Cr -2.33TCr
Projected Income Statement - Annual - CorMedix Inc.
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
20/26/20 $7.570 +2.57% 9,69,436
19/26/19 $7.380 +1.65% 14,72,392
16/26/16 $7.260 -2.68% 11,40,589
15/26/15 $7.460 +0.95% 14,66,252
14/26/14 $7.390 0.00% 11,24,915
Trader
Investor
Global
Quality
-
ESG MSCI
BB
MarketScreener Ratings - CorMedix Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.570USD
Average target price
15.33USD
Spread / Average Target
+102.55%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CorMedix Inc.
  1. Stock Market
  2. Stocks
  3. CRMD Stock